Dr. Hosoya is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Palo Alto, CA 94305Phone+1 650-498-6000
Education & Training
Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 2017 - 2019
Graduate School of Medicine and Faculty of Medicine, The University of TokyoClass of 2009
Certifications & Licensure
CA State Medical License 2019 - 2025
PA State Medical License 2016 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- 43 citationsEarly cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.Jennifer M Logue, Lauren C Peres, Hamza Hashmi, Christelle M Colin-Leitzinger, Alexandria M Shrewsbury
Blood Advances. 2022-12-27 - 197 citationsPRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3Ahmad Salameh, Alessandro K. Lee, Marina Cardó-Vila, Diana N. Nunes, Eleni Efstathiou
Proceedings of the National Academy of Sciences of the United States of America. 2015-07-07 - 12 citationsIdecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.Surbhi Sidana, Lauren C Peres, Hamza Hashmi, Hitomi Hosoya, Christopher Ferreri
Haematologica. 2024-03-01
Press Mentions
Society for Immunotherapy of Cancer Forward Fund Announces Recipients of Cancer Immunotherapy Fellowships and Technology AwardsAugust 12th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
